CRYOPORT, INC. Cash and Restricted Cash
CRYOPORT, INC. (CYRX) had Cash and Restricted Cash of $269.27 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $269.27M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $272.91M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $250.49M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $255.81M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $269.27M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $272.91M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $250.49M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $255.81M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $243.42M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $47.36M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $45.29M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $44.66M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $46.46M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $49.66M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $46.35M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $59.47M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $67.31M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $38.54M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $36.59M 10-K · filed 2026-03-05 | |
| 2022-09-30 | $30.72M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $37.03M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $134.45M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $139.10M 10-K · filed 2025-03-07 | |
| 2021-09-30 | $43.68M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $60.36M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $85.49M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $36.87M 10-K · filed 2024-03-13 | |
| 2020-09-30 | $161.99M 10-Q · filed 2021-11-04 | $161.99M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $44.33M 10-Q · filed 2021-08-06 | $44.33M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $50.62M 10-Q · filed 2021-05-06 | $50.62M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $47.23M 10-K · filed 2023-02-28 | $47.23M 10-K · filed 2020-03-10 |
| 2019-09-30 | $44.59M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $80.64M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $32.77M 10-Q · filed 2020-05-08 | |
| 2018-12-31 | $37.33M 10-K · filed 2022-02-28 | $37.33M 10-Q · filed 2019-08-09 |
| 2018-09-30 | $13.85M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $20.01M 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $15.04M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |